Helps replenish healthy gut bacteria. May help with bowel irregularities.
Oral supplements of live, beneficial intestinal micro-organisms for nutritional health and well-being are known as probiotics. Probiotic dietary lactobacilli colonize the intestinal tract. Bacteria are continually in competition for colonization space. The original bacterial colonies have an advantage over transient bacteria. Nevertheless, the composition of the intestinal microflora is dynamic and constantly changing. If harmful microorganisms proliferate, the equilibrium is disturbed, and it becomes difficult even for indigenous bacteria to maintain their necessary territory to colonize the intestine. Antibiotics tend to kill off both beneficial and harmful bacteria, and thus may also disturb the normal, healthy balance of intestinal microorganisms.
Various intestinal conditions can compromise the immune system and lower the amounts of healthy intestinal microflora. When potent probiotic supplements, such as Multi-Probiotic 15 Billion, are supplied regularly, chances are greatly increased for establishing and maintaining a healthy population of beneficial intestinal microorganisms†. Once established, a normal intestinal microflora rich in lactobacilli creates acidic conditions that are unfavorable for the settlement of pathogenic microorganisms.
Probiotics have been shown to exert a beneficial support through modification of the immune system host via the gut environment. Bifidobacterium lactis HN019 has been clinically shown in research to support the immune system by enhancing the function of leucocytes in adults and the elderly.† This strain may also help in the maintenance of bowel regularity and normal GI function.† Clinical trials also suggest that the exposure to microbes through the gastrointestinal tract powerfully shapes immune function. In particular, lactobacilli are considered to induce reactions involvingTh1 cells that benefit allergic diseases. Research on the L. gasseri strain supplementation has shown a beneficial effect on immunological reactions in school children. Lactobacillus rhamnosus is one of the most widely studied probiotics, noted and valued for its ability to survive in the harsh conditions of the digestive and urinary tracts. L. rhamnosus is extremely well tolerated by men and women with very rare side effects. Studies have shown that, taken regularly, L. rhamnosus can be an effective supplement in promoting and maintaining digestive tract health.
Primo Probiotic is acid and bile resistant and the cultures undergo a patented cyroprotectant stabilization process for shelf stability. For example, Bifidobacterium was studied in vitro to be extremely resistant to low pH and bile acids in the duodenum. L. acidophilus DDS-1 incorporates proprietary cryoprotectant agents and stabilizers specifically designed to protect the organism and enhance stability. Clinical analysis of DDS-1 and Bifidobacterium also shows increased binding to human intestinal walls and protective effects of intestinal colonization. Certain bacterial acids in the intestines produce secondary bile acids, which have been implicated as promoters of colon carcinogenesis. One study indicated that L. acidophilus DDS-1 decreased the potential for bacterial transformations of primary bile acid.
Prebiotics are carbohydrates that have short molecular chains. They function as non-digestible ingredients that can positively affect selected groups of beneficial intestinal microflora, such as lactobacillus. While probiotics merely add beneficial microflora, prebiotics affect the intestinal environment so that beneficial colonies of microflora can flourish. By aiding the beneficial microflora’s survival, pathogenic microflora can have a decreased chance of survival.
Primo Probiotic capsules may be a useful dietary supplement for those who wish to support their intestinal microflora with meaningful amounts of beneficial microorganisms.
Each Primo Probiotic capsule contains:
Multi-Strain Probiotic Blend ……..15 Billion CFU
Lactobacillus acidophilus (DDS-1).4.3 Billion CFU
Lactobacillus rhamnosus (Lr-32)….4.3 Billion CFU
Bifidobacterium lactis (HN019)…….1.9 Billion CFU
Lactococcus lactis (Ll-23)…………..1.0 Billion CFU
Bifidobacterium longum (Bl-05)…..1.0 Billion CFU
Bifidobacterium bifidum (Bb-02) …1.0 Billion CFU
Lactobacillus gasserri (Lg-36)……..1.0 Billion CFU
Streptococcus thermophilus (St-21) 0.5 Billion CFU
Digestive and Prebiotic Blend …………… 210 mg
FOS (fructooligosaccharides) and Ulmus fulva (bark)
Other Ingredients: Gelatin (capsule), cellulose, vegetable stearate and silica.
Adults take one capsule daily or as directed by a healthcare professional.
No adverse side effects have been reported.
Refrigerate after opening with lid tightly sealed. Keep out of reach of children.
Cebra JJ. Influences of microbiota on intestinal immune system development. Am J Clin Nutr Rerksuppaphol S, Rerksuppaphol L. Lactobacillus acidophilus and Bifidobacterium bifidum stored at ambient temperature are effective in the treatment of acute diarrhoea. Ann Trop Paediatr. 2010;30(4):299-304.
Mondot S, Kang S, Furet JP, Aguirre de Carcer D, McSweeney C, Morrison M,Marteau P, Doré J, Leclerc M. Highlighting new phylogenetic specificities of Crohn’s disease microbiota. Inflamm Bowel Dis. 2010 Aug 18.
Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, Song IS, Kim JS. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver.2009 Jun;3(2):101-7. Epub 2009 Jun 30.
Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterolgy. 2010 Apr 21;16(15):1908-15
Robert J Boyle, Roy M Robins-Browne and Mimi LK Tang. Probiotic use in clinical practice: what are the risks? American Journal of Clinical Nutrition, Vol. 83, No. 6, 1256-1264, June 2006
Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Therapeutic Advances in Gastroenterology 2010 3: 307-319
Rhode CL. The Use of Probiotics in the Prevention and Treatment of Antibiotic-Associated Diarrhea with Special Interest in Clostridium difficile-Associated Diarrhea. Nutr Clin Pract 2009 24: 33-40.
Chen YS, Jan RL, Lin YL, Chen HH, Wang JY. Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis. Pediatr Pulmonol. 2010 Nov;45(11):1111-20.
Multi-Probiotic 15 Billion
Cebra JJ. Influences of microbiota on intestinal immune system development. Am J Clin Nutr 1999;69:1046S-1051S.
Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999;69:1052S-1057S.
De Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol. 2008;111:1-66.
Gibson GR. Dietary modulation of the human gut microflora using prebiotics. Br J Nutr 1998;80:S209-12.
H.Lee, K.M.Shahani. Inhibitory Effect of Lactobacillus Acidophilus on transformation of bile acids by human fecal microflora. Microbiologie-Aliments-Nutrition.1995;13;241-247.
Murthy M, Venkitanarayan K.S., Rangavajhyala N and K.M. Shahani. Delineation of beneficial characteristics of effective probiotics. J. Am. Nutr. Assoc, 2000 3(2), 38-43
Ahmed, M et al. Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. J Nutr Health Aging. 2007 Jan-Feb;11(1):26-31.
Waller, Phillip et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults.Scand J Gastro, 2011; 46: 1057-64.
† These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.